Table 1.
Characteristics of included studies.
| Studies | Country | Study design | Time range | Samples (T/C)† | Age (T/C)‡, years | Treatment group | Control group | Median follow-up, mo. | Outcomes | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|
| Zeng et al. (21) | Mainland, China |
R | 2005–2009 | 12 (7/5) | NR | WBRT+TKI | Gefitinib | 23 | RR, DCR | 6 |
| Gerber et al. (22) | America | R | 2006–2012 | 110 (32/15/63) | 58 ± 11/61 ± 11/62 ± 13 | WBRT/SRS | erlotinib | 20 | OS, iPFS | 7 |
| Byeon et al. (23) | South Korea | R | 2005–2013 | 121 (59/62) | 60/60 | WBRT/SRS+TKI | Erlotinib/gefitinib | 18.4 | DCR, OS, iPFS | 7 |
| Chen et al. (24) | Mainland, China |
R | 2008–2014 | 132 (53/79) | 52/52 | WBRT+TKI | Erlotinib/gefitinib | 36.2 | RR, OS, iPFS | 7 |
| Jiang et al. (25) | Mainland, China |
R | 2012–2015 | 121(30/91) | NR | WBRT+TKI | Erlotinib/gefitinib/icotinib | NR | OS, iPFS | 5 |
| Magnuson et al. (9) | America | R | 2008–2014 | 50 (33/17) | 59/60 | WBRT/SRS+TKI | erlotinib | 20.6 | RR, OS, iPFS | 7 |
| Fan et al. (26) | Mainland, China |
R | 2011–2014 | 97 (56/41) | 56/59 | WBRT/SRS+TKI | icotinib | 28.5 | RR, OS, iPFS | 7 |
| Liu et al. (10) | Mainland, China |
R | 2008–2015 | 71 (NR) | NR | WBRT/SRS+TKI | Erlotinib/gefitinib/icotinib | 30 | OS | 6 |
| Magnuson (11) | America | R | 2008–2014 | 351 (120/100/131) | 58/63/60 | WBRT/SRS+TKI | TKI | 22 | OS, iPFS | 7 |
| Yang et al. (14) | Mainland, China |
RCT | 2012–2015 | 158 (73/85) | 58/57 | WBRT | icotinib | 16.5 | RR, DCR, OS, iPFS | C |
| Zhu et al. (12) | Mainland, China |
R | 2011–2015 | 133 (67/66) | 56 | WBRT/SRS+TKI | Erlotinib/gefitinib | 18 | OS, iPFS | 7 |
| Li et al. (27) | Taiwan, China | R | 2014–2016 | 28 (17/11) | 57.3 ± 9.4/62.0 ± 7.3 | WBRT+TKI | afatinib | 17.4 | RR, DCR, OS, iPFS | 7 |
| Sung et al. (28) | South Korea | R | 2008–2016 | 81 (40/41) | 64 | WBRT/SRS+TKI | Erlotinib/gefitinib | 20 | RR, DCR, OS, iPFS | 7 |
R, retrospective; RCT, randomized control trial; mo., months; NR, not reported; T, treatment group (upfront radiotherapy); C, control group (TKI alone); WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery; TKI, tyrosine kinase inhibitors; ORR, objective response rate; DCR, disease control rate; OS, overall survival; iPFS, intracranial progression-free survival.
†
The sample size is presented as “WBRT/SRS/TKI alone” or “WBRT or SRS/TKI alone,” according to the original study design of the included studies.
‡
The age is presented as “median age” or “mean age ±SD” for each group or the entire cohort.